234 related articles for article (PubMed ID: 30060548)
21. Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.
Wilkinson MJ; Smith HG; Pencavel TD; Mansfield DC; Kyula-Currie J; Khan AA; McEntee G; Roulstone V; Hayes AJ; Harrington KJ
Int J Cancer; 2016 Sep; 139(6):1414-22. PubMed ID: 27116656
[TBL] [Abstract][Full Text] [Related]
22. Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication.
Flores EB; Aksoy BA; Bartee E
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581062
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
[TBL] [Abstract][Full Text] [Related]
24. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
Lun X; Yang W; Alain T; Shi ZQ; Muzik H; Barrett JW; McFadden G; Bell J; Hamilton MG; Senger DL; Forsyth PA
Cancer Res; 2005 Nov; 65(21):9982-9990. PubMed ID: 16267023
[TBL] [Abstract][Full Text] [Related]
25. The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.
Liu J; Wennier S; McFadden G
Microbes Infect; 2010 Dec; 12(14-15):1144-52. PubMed ID: 20832500
[TBL] [Abstract][Full Text] [Related]
26. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.
Stanford MM; McFadden G
Expert Opin Biol Ther; 2007 Sep; 7(9):1415-25. PubMed ID: 17727330
[TBL] [Abstract][Full Text] [Related]
27. The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase.
Woo Y; Warner SG; Geha R; Stanford MM; Decarolis P; Rahman MM; Singer S; McFadden G; Fong Y
Clin Med Insights Oncol; 2021; 15():1179554921993069. PubMed ID: 33633477
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma.
Le Boeuf F; Selman M; Son HH; Bergeron A; Chen A; Tsang J; Butterwick D; Arulanandam R; Forbes NE; Tzelepis F; Bell JC; Werier J; Abdelbary H; Diallo JS
Int J Cancer; 2017 Sep; 141(6):1257-1264. PubMed ID: 28568891
[TBL] [Abstract][Full Text] [Related]
29. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
[TBL] [Abstract][Full Text] [Related]
30. Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.
Cecil A; Gentschev I; Adelfinger M; Nolte I; Dandekar T; Szalay AA
Bioengineered; 2014; 5(5):319-25. PubMed ID: 25482233
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
[TBL] [Abstract][Full Text] [Related]
32. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic Virotherapy with Myxoma Virus.
Rahman MM; McFadden G
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936317
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
35. Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.
Ashton LV; Graham B; Afzali MF; Gustafson D; MacNeill AL
Oncolytic Virother; 2020; 9():17-29. PubMed ID: 32548076
[TBL] [Abstract][Full Text] [Related]
36. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.
Wang G; Barrett JW; Stanford M; Werden SJ; Johnston JB; Gao X; Sun M; Cheng JQ; McFadden G
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4640-5. PubMed ID: 16537421
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic Viruses for Canine Cancer Treatment.
Sánchez D; Cesarman-Maus G; Amador-Molina A; Lizano M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30373251
[TBL] [Abstract][Full Text] [Related]
39. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
40. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
